Bayer and Zydus extend their JV for three years
The joint venture will continue to operate in therapies including cardiology, diabetes, women’s health, ophthalmology and…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Diabetes
Biocon Biologics partners with IDF to improve access to insulins
The partnership coincides with the start of the centenary celebrations of the discovery of insulin
Rise in sale of heart and diabetes drugs, immunity boosters in November: Pronto Consult survey
The survey of over 3000 retailers across the country provides information about the consumer's buying pattern and preferences
Biocon Biologics signs MoU with CSSC in Tanzania for Mission 10 cents, affordable insulins programme
The programme is expected to roll-out early next year
Drug used to treat opioid addiction can reverse some adverse events caused by type 2 diabetes: Study
IIT Mandi researchers find that low-dose naltrexone (LDN) can activate SIRT1, a critical protein molecule, thereby reducing…
Biocon Biologics and Mylan launch Semglee (insulin glargine injection) in US
Mylan is offering Semglee at a wholesale acquisition cost (WAC) of $147.98 per package of five 3ml pens and $98.65 per 10ml vial
Biocon’s Malaysia Insulin glargine facility receives Certificate of GMP
The approval expands Biocon’s capacities, with new large scale devices facility coming up to speed to serve growing needs of…
Biocon collaborates with JDRF
JDRF provides financial support to accelerate breakthrough research in Type 1 Diabetes management
DDCR in research collaboration with RBPL
To explore new possibilities in diabetes research
Type 1 Diabetes may up epilepsy risk by three times: Study
Immune abnormalities, brain lesions, genetic factors and metabolic abnormalities are all potential causes for the link between…